Back to Search
Start Over
Rapamycin improves Graves' orbitopathy by suppressing CD4+ cytotoxic T lymphocytes.
- Source :
-
JCI insight [JCI Insight] 2023 Feb 08; Vol. 8 (3). Date of Electronic Publication: 2023 Feb 08. - Publication Year :
- 2023
-
Abstract
- CD4+ cytotoxic T lymphocytes (CTLs) were recently implicated in immune-mediated inflammation and fibrosis progression of Graves' orbitopathy (GO). However, little is known about therapeutic targeting of CD4+ CTLs. Herein, we studied the effect of rapamycin, an approved mTOR complex 1 (mTORC1) inhibitor, in a GO mouse model, in vitro, and in patients with refractory GO. In the adenovirus-induced model, rapamycin significantly decreased the incidence of GO. This was accompanied by the reduction of both CD4+ CTLs and the reduction of orbital inflammation, adipogenesis, and fibrosis. CD4+ CTLs from patients with active GO showed upregulation of the mTOR pathway, while rapamycin decreased their proportions and cytotoxic function. Low-dose rapamycin treatment substantially improved diplopia and the clinical activity score in steroid-refractory patients with GO. Single-cell RNA-Seq revealed that eye motility improvement was closely related to suppression of inflammation and chemotaxis in CD4+ CTLs. In conclusion, rapamycin is a promising treatment for CD4+ CTL-mediated inflammation and fibrosis in GO.
Details
- Language :
- English
- ISSN :
- 2379-3708
- Volume :
- 8
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- JCI insight
- Publication Type :
- Academic Journal
- Accession number :
- 36580373
- Full Text :
- https://doi.org/10.1172/jci.insight.160377